Author

Xiaoxia Wang

Observed name: Wang, Xiaoxia

Institutions: Shanxi Medical University, Capital Medical University, Second Hospital of Shanxi Medical University, Beijing YouAn Hospital

Observed institutions: Shanxi Medical University, Capital Medical University, Second Hospital of Shanxi Medical University, Beijing YouAn Hospital

ORCID: 0000-0002-7473-6649

Observed ORCID: 0000-0002-7473-6649

OpenAlex ID: A5010056071

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

2023 · Di Wu, Jing Li, et al. · Annals of the Rheumatic Diseases · 166

Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis

2025 · Tian Liu, Li Wang, et al. · JAMA Network Open · 17

Effects of Probiotic Preparations on Inflammatory Cytokines in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis

2020 · Ting Liu, Xiaoxia Wang, et al. · Current Pharmaceutical Biotechnology · 14

CD163 in Macrophages: A Potential Biomarker for Predicting the Progression of Diabetic Nephropathy based on Bioinformatics Analysis

2022 · Xiaodong Zhang, Xiaoxia Wang, et al. · Endocrine Metabolic & Immune Disorders - Drug Targets · 9

Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial

2025 · Xu Liu, Liling Xu, et al. · Arthritis & Rheumatology · 7

Identification of Novel Hub Genes Associated with Inflammation and Autophagy in Astragaloside Membranaceus ameliorates Lupus Nephritis by Bioinformatics Analysis and Molecular Dynamics Simulation

2024 · Kaili Kong, Xiaomei Qiao, et al. · Combinatorial Chemistry & High Throughput Screening · 4

Effects of FABP5 Expression on Clinicopathological and Survival Characteristics in Digestive System Malignancies: A Systematic Review and Meta‐Analysis

2025 · Miaoqing Li, Xiaoxia Wang, et al. · Cancer Medicine · 2

Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study

2025 · Shangzhu Zhang, Dong Xu, et al. · BioDrugs · 1

Efficacy and safety of XKH004, a novel dual interleukin-17A/F inhibitory monoclonal antibody, in active ankylosing spondylitis: A 52-week phase 3 randomized study

2026 · Ling Zhou, Ran Yan, et al. · hLife

Lenvatinib Versus Bevacizumab in Combination With Anti‐ PD ‐1/ PD ‐ L1 Therapy for uHCC : A Meta‐Analysis of East Asian Studies

2026 · Xiaoxia Wang, Shuo Wang, et al. · Liver International

Works count: 12

Citation count: 219

H-index: 5

I10-index: 3